BCTX BriaCell Therapeutics Corp.: Net earnings per share for the last 12 months

Public company logo of BriaCell Therapeutics Corp (BCTX)

BriaCell Therapeutics (BCTX) management is scaling clinical trials, which is temporarily increasing current expenditures. The trailing twelve months (ttm) net income per share growth rate visualizes the results of this strategy, where 88.10 shows the value of this parameter. Oncology experts ensure process transparency for investors, while innovative developments in the US and Canada create a foundation for the fight against breast cancer.

BriaCell Therapeutics Corp. (BCTX): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

BCTX (BriaCell Therapeutics): analytical breakdowns and indicator data

Fundamental company valuation:BCTX (BriaCell)
Flagship merchandise of BriaCell Corp

When constructing a long-term portfolio, asset screening requires an analysis of earnings resilience amid liquidity contraction and high Fed rates. This indicator measures the percentage change in net income per share over the last twelve months, reflecting the efficiency of BriaCell Therapeutics (BCTX) in capitalizing on innovations in personalized cancer immunotherapy via the annual EPS TTM delta.